FROM CRITICAL EQUIPMENT TO
TOTAL PROCESS SOLUTION
Successful Open Day at Bioengineering
Time:2026-07-08 15:21:33

On June 30, 2026, Bioengineering opened the doors of its facility in Wald (ZH) and welcomed customers, partners, and interested professionals to an Open House focused entirely on the latest product developments.

Numerous guests took the opportunity to learn about the new generation of Taberis benchtop bioreactors as well as other innovations from our single-use portfolio.

The focus was on the Taberis Parasmart, Taberis Prime, and Taberis Xpert systems, which were presented live and demonstrated in practical use. The exhibition was complemented by our Bagento and Ondalis solutions, further expanding Bioengineering's single-use portfolio.

During the live demonstrations, visitors gained direct insight into the various applications of the systems—from rapid screening and an easy introduction to bioprocess technology to precise process control for demanding applications

Just as valuable as the product presentations were the personal exchanges. The numerous technical discussions provided an opportunity to discuss individual requirements, share experiences, and explore specific questions in depth together.

We would like to extend our sincere thanks to all visitors for their interest and the many stimulating conversations. Your positive feedback and open dialogue made our Open Day a resounding success.

About Bioengineering AG

Bioengineering AG is a global leader in bioreactor technology. With over 50 years of dedicated expertise, the company has built a strong international reputation for professional excellence. Today, Bioengineering AG serves clients worldwide, offering comprehensive solutions that cover the full spectrum of bioreaction and cultivation needs—from laboratory research and pilot-scale development to commercial-scale production. In 2025, Bioengineering AG officially joined the Morimatsu. By synergizing its deep technological foundation with collaborative innovation, the company is committed to driving high-quality, sustainable development across the pharmaceutical, biopharmaceutical, and synthetic biology industries.